SeeThruEquity has issued an update and $0.65 price target on shares of Innovus Pharmaceuticals, Inc. (OTCQB: INNV) following the company’s launch of AllerVarx™ in the U.S. and the report of financial results for the first quarter of 2017. Highlights from the report include revenue of $2.2 million, a 865% increase compared to $0.2 million for the same period of the previous year. The analyst said the increase demonstrates sustained sales execution, placing Innovus on track to achieve its full-year guidance for $10 million – $15 million. The company is also expanding sales channels for its portfolio of 18 commercial products.
For more information, visit www.innovuspharma.com
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which it markets directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through on-line channels, retailers and wholesalers. The company is dedicated to developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer